Designing for simplicity: lessons from Mesa Biotech for microfluidic entrepreneurs and early-stage companies.
Lab Chip
; 22(8): 1469-1473, 2022 04 12.
Article
in English
| MEDLINE | ID: covidwho-1805673
ABSTRACT
The COVID-19 pandemic has proven the need for point-of-care diagnosis of respiratory diseases and microfluidic technology has risen to the occasion. Mesa Biotech (San Diego, CA) originally developed the Accula platform for the diagnosis of influenza A and B and then extended the platform to SARS-CoV-2. Mesa Biotech has experienced tremendous success, culminating in acquisition by Thermo Fisher for up to $550m USD. The Accula microfluidics platform accomplished the leap from the lab to commercial product through clever design and engineering choices. Through information obtained from interviews with key Mesa Biotech leaders and publicly-available documents, we describe the keys to Mesa's success and how they might inform other lab-on-a-chip companies.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pandemics
/
COVID-19
Type of study:
Diagnostic study
Limits:
Humans
Language:
English
Journal:
Lab Chip
Journal subject:
Biotechnology
/
Chemistry
Year:
2022
Document Type:
Article
Affiliation country:
D2lc00081d
Similar
MEDLINE
...
LILACS
LIS